UY29186A1 - Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) - Google Patents

Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)

Info

Publication number
UY29186A1
UY29186A1 UY29186A UY29186A UY29186A1 UY 29186 A1 UY29186 A1 UY 29186A1 UY 29186 A UY29186 A UY 29186A UY 29186 A UY29186 A UY 29186A UY 29186 A1 UY29186 A1 UY 29186A1
Authority
UY
Uruguay
Prior art keywords
inhibitors
new
vegf
pyridinures
antranilamide
Prior art date
Application number
UY29186A
Other languages
English (en)
Inventor
Karl-Heinz Thierauch
Martin Haberey
Andreas Reichel
Rolf Bohlmann
Andreas Huth
Holger Hess-Stumpp
Stuart Ince
Martin Krueger
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928840&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29186(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY29186A1 publication Critical patent/UY29186A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del VEGF, su producción y su uso como agentes farmacéuticos para tratar enfermedades desencadenadas por una angiogénesis persistente.
UY29186A 2004-11-03 2005-10-31 Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) UY29186A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04090419A EP1655295A1 (en) 2004-11-03 2004-11-03 Anthranilamide pyridinureas as VEGF receptor kinase inhibitors

Publications (1)

Publication Number Publication Date
UY29186A1 true UY29186A1 (es) 2006-05-31

Family

ID=34928840

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29186A UY29186A1 (es) 2004-11-03 2005-10-31 Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)

Country Status (23)

Country Link
US (2) US7902229B2 (es)
EP (2) EP1655295A1 (es)
JP (1) JP4988584B2 (es)
KR (1) KR101280809B1 (es)
CN (1) CN101052634B (es)
AR (1) AR051413A1 (es)
AU (1) AU2005300736B2 (es)
BR (1) BRPI0517963A2 (es)
CA (1) CA2586271C (es)
GT (1) GT200500316A (es)
HK (1) HK1109403A1 (es)
IL (1) IL182399A0 (es)
MX (1) MX2007005339A (es)
MY (1) MY147642A (es)
NO (1) NO20072804L (es)
PA (1) PA8651301A1 (es)
PE (1) PE20060727A1 (es)
RU (1) RU2415850C2 (es)
SV (1) SV2006002288A (es)
TW (1) TWI409066B (es)
UY (1) UY29186A1 (es)
WO (1) WO2006048251A1 (es)
ZA (1) ZA200705009B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
DE10023486C1 (de) * 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US7615565B2 (en) * 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7202260B2 (en) * 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) * 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1655297A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
RU2008126228A (ru) 2005-11-30 2010-01-10 Астеллас Фарма Инк. (Jp) 2-аминобензамидное производное
EP2008658A1 (en) * 2007-06-28 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Synergistic combination of anthranilamide pyridinureas and benzamide derivatives
KR20110045095A (ko) * 2008-08-27 2011-05-03 레오 파마 에이/에스 Ｖｅｇｆｒ-2 수용체 및 단백질 티로신 키나아제 억제제인 피리딘 유도체
EP2712862A1 (en) * 2012-09-28 2014-04-02 Splicos New anti-invasive compounds
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
CN103739550B (zh) * 2014-01-02 2016-06-01 中国药科大学 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
CN103936719A (zh) * 2014-05-14 2014-07-23 中国药科大学 苯并咪唑类衍生物制备方法及用途
EP3174868B1 (en) 2014-08-01 2021-08-25 Nuevolution A/S Compounds active towards bromodomains
JP7129420B6 (ja) 2017-03-30 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｐｋ１阻害剤としてのイソキノリン
CN109942544B (zh) * 2017-12-21 2021-06-11 中国科学院合肥物质科学研究院 一类新型吲唑类衍生物激酶抑制剂
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226394A (en) 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
JPS5744672B2 (es) 1974-05-24 1982-09-22
DE2652144A1 (de) 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
EP0117462A3 (en) 1983-02-28 1986-08-20 American Cyanamid Company N-(2-4-(1h-imidazol-1-yl)alkyl)arylamides
US4568687A (en) 1983-02-28 1986-02-04 American Cyanamid Company N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions
FR2689508B1 (fr) 1992-04-01 1994-06-17 Fournier Ind & Sante Derives de l'imidazole, leur procede de preparation et leur application en therapeutique.
AU6910994A (en) 1993-05-14 1994-12-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
RU2128644C1 (ru) 1993-12-27 1999-04-10 Эйсай Ко., Лтд. Производные антраниловой кислоты или их фармакологически приемлемые соли, промежуточные продукты для их получения и лекарственный препарат на их основе
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DE19910396C2 (de) 1999-03-03 2001-12-13 Schering Ag Anthranilsäureamide und deren Verwendung als Arzneimittel
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
JP2002533454A (ja) 1998-12-23 2002-10-08 イーライ・リリー・アンド・カンパニー 芳香族アミド類
CA2363084A1 (en) * 1999-02-22 2000-08-31 Gernot Treusch Therapeutically effective substance mixture
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
DE10023485A1 (de) 2000-05-09 2001-11-22 Schering Ag Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
DE10023484A1 (de) 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
DE10023492A1 (de) 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
JP2004521878A (ja) 2000-12-07 2004-07-22 スィーヴィー　セラピューティクス　インコーポレイテッド Ａｂｃａ−１を上昇させる化合物
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
JP4343681B2 (ja) 2001-05-08 2009-10-14 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト シアノアントラニルアミド誘導体およびそれらの薬剤としての使用
EP1389201A1 (de) * 2001-05-08 2004-02-18 Schering Aktiengesellschaft N-oxidanthranylamid-derivate und deren verwendung als arzneimittel
DE50213703D1 (de) * 2001-05-08 2009-09-03 Bayer Schering Pharma Ag Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren
GB0126902D0 (en) 2001-11-08 2002-01-02 Novartis Ag Organic compounds
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
JP2003250770A (ja) * 2002-02-28 2003-09-09 Omron Corp 電子血圧計
US20040039019A1 (en) 2002-06-19 2004-02-26 Schering Ag Selected anthranilaminde pyridinamides and their use as pharmaceutical agents
DE10228090A1 (de) 2002-06-19 2004-01-15 Schering Ag Ausgewählte Anthranylamidpyridinamide und deren Verwendung als Arzneimittel
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
AU2003281855A1 (en) * 2002-07-31 2004-02-23 Schering Aktiengesellschaft Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
US7148357B2 (en) * 2002-07-31 2006-12-12 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7517894B2 (en) 2002-07-31 2009-04-14 Bayer Schering Pharma Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7202260B2 (en) 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors

Also Published As

Publication number Publication date
CN101052634B (zh) 2011-05-18
AU2005300736B2 (en) 2012-01-19
RU2007120692A (ru) 2008-12-10
BRPI0517963A2 (pt) 2009-03-24
WO2006048251A1 (en) 2006-05-11
US7902229B2 (en) 2011-03-08
GT200500316A (es) 2006-06-06
PA8651301A1 (es) 2006-07-03
AU2005300736A1 (en) 2006-05-11
MX2007005339A (es) 2007-08-17
EP1807413A1 (en) 2007-07-18
TW200621714A (en) 2006-07-01
RU2415850C2 (ru) 2011-04-10
TWI409066B (zh) 2013-09-21
JP4988584B2 (ja) 2012-08-01
US20060116380A1 (en) 2006-06-01
KR101280809B1 (ko) 2013-07-02
NO20072804L (no) 2007-08-03
KR20070085610A (ko) 2007-08-27
JP2008518894A (ja) 2008-06-05
EP1655295A1 (en) 2006-05-10
AR051413A1 (es) 2007-01-10
CN101052634A (zh) 2007-10-10
ZA200705009B (en) 2014-12-23
US20110124680A1 (en) 2011-05-26
PE20060727A1 (es) 2006-08-04
HK1109403A1 (en) 2008-06-06
CA2586271A1 (en) 2006-05-11
MY147642A (en) 2012-12-31
SV2006002288A (es) 2006-06-26
CA2586271C (en) 2013-08-06
IL182399A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
UY29186A1 (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
CL2009000133A1 (es) Compuestos derivados de ftalazinona, inhibidores de la actividad parp; composicion farmaceutica; uso en el tratamiento de enfermedades vasculares, shock septico, lesion isquemica, neurotoxicidad, shock hemorragico, como auxiliar en la terapia del cancer de mama, de ovario, de pancreas, entre otras.
UY30779A1 (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
ECSP12011716A (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
NO20072802L (no) Nye antranilamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF) -reseptorkinaseinhibitorer
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
ECSP099357A (es) COMPUESTOS QUE MODULAN ACTIVIDAD C-FMS y/o C-KIT Y USOS PARA ELLO
UY31430A1 (es) Derivados de piridina y pirazina -83
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
CL2009001160A1 (es) Compuestos derivados de heterociclos nitrogenados fusionados y su composicion farmaceutica.
CR20120289A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
GT200600081A (es) Derivados de acetilenno
BRPI0515725A (pt) piridinuréias de nicotinamida como inibidoras de cinase de receptor do fator de crescimento endotelial vascular (vegf)
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
AR066701A1 (es) 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia
CO6361926A2 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
CL2015000119A1 (es) El compuesto (r)-1-(1-(metil-sulfonil)-propan-2-il)-4-(trifluoro-metil)-1h-indol-5-carbonitrilo, modulador del receptor de androgeno; composicion farmaceutica; y su uso para tratar consuncion muscular asociada con epoc, con enfermedad cronica del riñon, con insuficiencia cardiaca cronica, e incontinencia urinaria, y para acelerar la reparacion y sanado de fractura de cadera.
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160525